Filter
1056
Filtered Results: 1056
Text search:
Anti-Tuberculosis
medicines
Featured
Recommendations
138
New Publications
379
Language
Document type
No document type
701
Guidelines
128
Studies & Reports
114
Manuals
52
Strategic & Response Plan
24
Fact sheets
12
Training Material
11
Situation Updates
10
Infographics
3
Resource Platforms
1
Countries / Regions
India
66
Kenya
38
Uganda
33
Western and Central Europe
31
Ethiopia
27
Global
25
Ghana
24
Zambia
24
Tanzania
23
South Africa
23
Liberia
21
Nigeria
21
Eastern Europe
21
Nepal
19
Myanmar / Burma
18
Malawi
17
Namibia
17
Philippines
13
Rwanda
13
Bangladesh
13
Sierra Leone
12
Ukraine
11
Asia
11
Africa
11
Zimbabwe
10
Cambodia
10
Latin America and the Carribbean
10
Lesotho
9
Russia
9
Botswana
7
South–East Asia Region
7
Venezuela
7
Pakistan
5
Mozambique
5
Eswatini/ Swaziland
5
Syria
4
Colombia
4
East and Southern Africa
4
Senegal
3
Cameroon
3
Afghanistan
3
Thailand
3
Indonesia
3
Vietnam
3
Haiti
2
Somalia
2
Jordan
2
Lebanon
2
Bolivia
2
Libya
2
Yemen
2
Eastern Europe and Central Asia
2
Poland
2
Albania
2
Tajikistan
2
Moldova
2
Turkmenistan
2
Burkina Faso
1
Congo, Democratic Republic of
1
Mali
1
Saudi Arabia
1
Iraq
1
Germany
1
Egypt
1
Gambia
1
Papua New Guinea
1
Sudan
1
Benin
1
Argentina
1
Peru
1
Brazil
1
North Macedonia
1
Hungary
1
Sri Lanka
1
Chile
1
West and Central Africa
1
Middle East and North Africa
1
Western Pacific Region
1
Paraguay
1
Solomon Islands
1
Bhutan
1
Palestine
1
Djibouti
1
Southern Africa
1
Laos
1
Timor Leste/ East Timor
1
Qatar
1
Iran
1
Georgia
1
North America
1
Denmark
1
Maldives
1
Authors & Publishers
Publication Years
Category
Countries
482
Clinical Guidelines
123
Public Health
55
Women & Child Health
34
Pharmacy & Technologies
15
Key Resources
14
Capacity Building
10
Toolboxes
TB
230
HIV
107
AMR
61
Pharmacy
60
COVID-19
25
Mental Health
23
NCDs
19
Caregiver
18
Global Health Education
15
NTDs
14
Refugee
12
Conflict
11
Polio
9
Rapid Response
6
Planetary Health
6
Disability
5
Ebola
5
Health Financing Toolbox
5
Specific Hazards
2
Natural Hazards
1
Health Financing
1
Early-warning indicators to prevent stock-outs and overstocking of antiretroviral, antituberculosis and antimalaria medicines.
9 June 2021
Since its launch, GLASS has expanded in scope and coverage and as of May 2021, 109 countries and territories worldwide have enrolled in GLASS. A key new component in GLASS is the inclusion of antimicrobial consumption (AMC) surveillance at the national level highlighted in this fourth G...
In Kenya, the bacterial infections that contribute most to human disease are often those in which re-‐sistance is most evident. Examples are multidrug-‐resistant enteric bacterial pathogens such as typhoid, ...
DR-TB drugs under the microscope: Sources and prices for drug-resistant tuberculosis medicines
recommended
4th edition.
This report – now in its fourth edition – analyses the barriers and factors affecting access to treatment regimens for drug-resistant tuberculosis (DR-TB), including new and repurposed drugs. We provide detailed pricing profiles of...
Technical information note. Ensuring an uninterrupted supply of quality-assured, affordable anti-TB
drugs and diagnostics to the world
The first important change is a new priority ranking of the available medicines for MDR-TB treatment, based on a careful balance between expected benefits and harms. Treatment success for MDR-TB is currently low in many countries. This could be incr...
2nd edition. Children with TB comprise about 10-12% of the total TB cases diagnosed in the country. This burden is likely to be higher given the challenges in diagnosing TB in children. The symptoms of TB in children mimic those of other childhood diseases. Children do not readily expectorate and th...
This article examines the activities of national and international actors in Pharmaceutical Services (PS) in Mozambique from 2007 to 2012, focusing on the public provision of HIV/Aids, malaria and tuberculosis .... It describes how PS functions in the country, what actors are involved in this area and the relations among them, pursuing salient issues in the modus operandi of partners in cooperation.
Ensuring Access to Simple, Safe and Effective First-Line Medicines for Tuberculosis.
Accessed in November 2017.
GDF is the largest global provider of quality-assured tuberculosis (TB)
medicines, diagnostics, and laboratory supplies to the public sector.
Since 2001, GDF has facilitated access to high-quality...
Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant
tuberculosis (XDR-TB) increasingly occur in resource-constrained settings.
In the context of a national response to MDR- an...
N Engl J Med 2022; 386:911-922, DOI: 10.1056/NEJMoa2104535
Four months of antituberculosis treatment was noninferior to 6 months of treatment in children with drug-susceptible, nonsevere, smear-negative t... (SHINE Study)
Antimicrobial resistant (AMR) organisms are increasing globally, threatening to render existing treatments ineffective against many infectious diseases. In Africa, AMR has already been documented to be a problem for HIV and the pathogens that cause malaria, ..., typhoid, cholera, meningitis, gonorrhea, and dysentery. Recognizing the urgent need for action, the World Health Assembly adopted the Global Action Plan on Antimicrobial Resistance in May 2015. In accordance with the Global Action Plan and to meet needs specific to Africa, Africa CDC will establish the Anti-Microbial Resistance Surveillance Network (AMRSNET). AMRSNET is a network of public health institutions and leaders from human and animal health sectors who will collaborate to measure, prevent, and mitigate harms from AMR organisms.
Report: A survey conducted among the 27 high MDR-TB burden countries.
March – July 2015
Stop TB Partnership in collaboration with Medecins Sans Frontieres (MSF).
Accessed November 2017.
